Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States

Carla V. Rodriguez-Watson, Natalie E. Sheils, Anthony M. Louder, Elizabeth H. Eldridge, Nancy D. Lin, Benjamin D. Pollock, Jennifer L. Gatz, Shaun J. Grannis, Rohit Vashisht, Kanwal Ghauri, Gina Valo, Aloka G. Chakravarty, Tamar Lasky, Mary Jung, Stephen L. Lovell, Jacqueline M. Major, Carly Kabelac, Camille Knepper, Sandy Leonard, Peter J. EmbiWilliam G. Jenkinson, Reyna Klesh, Omai B. Garner, Ayan Patel, Lisa Dahm, Aiden Barin, Dan M. Cooper, Tom Andriola, Carrie L. Byington, Bridgit O. Crews, Atul J. Butte, Jeff Allen

Research output: Contribution to journalArticlepeer-review


Background As diagnostic tests for COVID-19 were broadly deployed under Emergency Use Authorization, there emerged a need to understand the real-world utilization and performance of serological testing across the United States. Methods Six health systems contributed electronic health records and/or claims data, jointly developed a master protocol, and used it to execute the analysis in parallel. We used descriptive statistics to examine demographic, clinical, and geographic characteristics of serology testing among patients with RNA positive for SARS-CoV-2. Results Across datasets, we observed 930,669 individuals with positive RNA for SARS-CoV-2. Of these, 35,806 (4%) were serotested within 90 days; 15% of which occurred <14 days from the RNA positive test. The proportion of people with a history of cardiovascular disease, obesity, chronic lung, or kidney disease; or presenting with shortness of breath or pneumonia appeared higher among those serotested compared to those who were not. Even in a population of people with active infection, race/ethnicity data were largely missing (>30%) in some datasets—limiting our ability to examine differences in serological testing by race. In datasets where race/ethnicity information was available, we observed a greater distribution of White individuals among those serotested; however, the time between RNA and serology tests appeared shorter in Black compared to White individuals. Test manufacturer data was available in half of the datasets contributing to the analysis. Conclusion Our results inform the underlying context of serotesting during the first year of the COVID-19 pandemic and differences observed between claims and EHR data sources–a critical first step to understanding the real-world accuracy of serological tests. Incomplete reporting of race/ethnicity data and a limited ability to link test manufacturer data, lab results, and clinical data challenge the ability to assess the real-world performance of SARS-CoV-2 tests in different contexts and the overall U.S. response to current and future disease pandemics.

Original languageEnglish (US)
Article numbere0281365
JournalPloS one
Issue number2 February
StatePublished - Feb 2023

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Real-world utilization of SARS-CoV-2 serological testing in RNA positive patients across the United States'. Together they form a unique fingerprint.

Cite this